Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs
Open Access
- 22 November 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 218 (suppl_5) , S603-S611
Abstract
Filoviruses including Ebola, Sudan, and other species are emerging zoonotic pathogens representing a significant public health concern with high outbreak potential, and they remain a potential bioterrorism-related threat. We have developed a despeciated equine Ebola polyclonal antibody (E-EIG) postexposure treatment against Ebola virus (EBOV) and evaluated its efficacy in the guinea pig model of EBOV infection. Guinea pigs were infected with guinea pig-adapted EBOV (Mayinga strain) and treated with various dose levels of E-EIG (20–100 mg/kg) twice daily for 6 days starting at 24 h postinfection. The E-EIG was also assessed for neutralization activity against related filoviruses including EBOV strains Mayinga, Kikwit, and Makona and the Bundibugyo and Taï Forest ebolavirus species. Treatment with E-EIG conferred 83% to 100% protection in guinea pigs. The results demonstrated a comparable neutralization activity (range, 1:512–1:896) of E-EIG against all tested strains, suggesting the potential for cross-protection with the polyclonal antibody therapeutic. This study showed that equine-derived polyclonal antibodies are efficacious against lethal EBOV disease in a relevant animal model. Furthermore, the studies support the utility of the equine antibody platform for the rapid production of a therapeutic product in the event of an outbreak by a filovirus or other zoonotic pathogen.Keywords
Funding Information
- Canadian Institutes of Health Research (352358)
- Public Health Agency of Canada
- National Institute for Allergy and Infectious Diseases (R01AI126587)
This publication has 39 references indexed in Scilit:
- Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody CocktailScience Translational Medicine, 2013
- Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesProceedings of the National Academy of Sciences, 2012
- Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic FeverPLOS ONE, 2012
- Postexposure antibody prophylaxis protects nonhuman primates from filovirus diseaseProceedings of the National Academy of Sciences, 2012
- Advances in Virus-Like Particle Vaccines for FilovirusesThe Journal of Infectious Diseases, 2011
- Impact of Ebola Mucin-Like Domain on Antiglycoprotein Antibody Responses Induced by Ebola Virus-Like ParticlesThe Journal of Infectious Diseases, 2011
- Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus GlycoproteinPLOS Pathogens, 2010
- Ebolavirus Glycoprotein GP Masks both Its Own Epitopes and the Presence of Cellular Surface ProteinsJournal of Virology, 2009
- Filovirus‐Like Particles Produced in Insect Cells: Immunogenicity and Protection in RodentsThe Journal of Infectious Diseases, 2007
- Evaluation of Immune Globulin and Recombinant Interferon‐α2b for Treatment of Experimental Ebola Virus InfectionsThe Journal of Infectious Diseases, 1999